生物技术公司Genprex, Inc.近日披露了其候选药物Gpx-002在2型糖尿病动物模型中取得的积极初步临床前研究结果。该数据显示,Gpx-002在改善糖尿病相关关键指标方面表现出潜力,为后续开发提供了支持。公司计划基于这些数据推进进一步的研究。
生物技术公司Genprex, Inc.近日披露了其候选药物Gpx-002在2型糖尿病动物模型中取得的积极初步临床前研究结果。该数据显示,Gpx-002在改善糖尿病相关关键指标方面表现出潜力,为后续开发提供了支持。公司计划基于这些数据推进进一步的研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.